Tanaka S - Search Results

1

Assessment of urinary angiotensinogen as a marker of podocyte injury in proteinuric nephropathies.

Eriguchi M, Yotsueda R, Torisu K, Kawai Y, Hasegawa S, Tanaka S, Noguchi H, Masutani K, Kitazono T, Tsuruya K. Eriguchi M, et al. Among authors: tanaka s. Am J Physiol Renal Physiol. 2016 Feb 15;310(4):F322-33. doi: 10.1152/ajprenal.00260.2015. Epub 2015 Dec 2. Am J Physiol Renal Physiol. 2016. PMID: 26632605 Free article.

We previously described the elevation of urinary angiotensinogen (AGT) accompanied by AGT expression by injured podocytes in a nitric oxide inhibition rat model (Eriguchi M, Tsuruya K, Haruyama N, Yamada S, Tanaka S, Suehiro T, Noguchi H, Masutani K, Torisu K …

We previously described the elevation of urinary angiotensinogen (AGT) accompanied by AGT expression by injured podocytes in a nitric oxide …

2

Effectiveness of lanthanum carbonate treatment used in combination with other phosphate binders in peritoneal dialysis patients.

Yamada S, Yoshida H, Taniguchi M, Tanaka S, Eriguchi M, Nakano T, Tsuruya K, Kitazono T. Yamada S, et al. Among authors: tanaka s. Intern Med. 2012;51(16):2097-104. doi: 10.2169/internalmedicine.51.6814. Epub 2012 Aug 15. Intern Med. 2012. PMID: 22892485 Free article.

3

The clinical utility of serum tartrate-resistant acid phosphatase 5b in the assessment of bone resorption in patients on peritoneal dialysis.

Yamada S, Tsuruya K, Yoshida H, Taniguchi M, Haruyama N, Tanaka S, Eriguchi M, Nakano T, Kitazono T. Yamada S, et al. Among authors: tanaka s. Clin Endocrinol (Oxf). 2013 Jun;78(6):844-51. doi: 10.1111/cen.12070. Epub 2013 Apr 6. Clin Endocrinol (Oxf). 2013. PMID: 23078546

4

Development and validation of a prediction rule using the Oxford classification in IgA nephropathy.

Tanaka S, Ninomiya T, Katafuchi R, Masutani K, Tsuchimoto A, Noguchi H, Hirakata H, Tsuruya K, Kitazono T. Tanaka S, et al. Clin J Am Soc Nephrol. 2013 Dec;8(12):2082-90. doi: 10.2215/CJN.03480413. Epub 2013 Oct 31. Clin J Am Soc Nephrol. 2013. PMID: 24178970 Free PMC article.

5

Relationship between residual renal function and serum fibroblast growth factor 23 in patients on peritoneal dialysis.

Yamada S, Tsuruya K, Taniguchi M, Yoshida H, Tokumoto M, Hasegawa S, Tanaka S, Eriguchi M, Nakano T, Kitazono T. Yamada S, et al. Among authors: tanaka s. Ther Apher Dial. 2014 Oct;18(5):383-90. doi: 10.1111/1744-9987.12170. Epub 2014 Mar 27. Ther Apher Dial. 2014. PMID: 24674095

6

Renal denervation has blood pressure-independent protective effects on kidney and heart in a rat model of chronic kidney disease.

Eriguchi M, Tsuruya K, Haruyama N, Yamada S, Tanaka S, Suehiro T, Noguchi H, Masutani K, Torisu K, Kitazono T. Eriguchi M, et al. Among authors: tanaka s. Kidney Int. 2015 Jan;87(1):116-27. doi: 10.1038/ki.2014.220. Epub 2014 Jun 18. Kidney Int. 2015. PMID: 24940798 Free article.

7

Impact of combined losartan/hydrochlorothiazide on proteinuria in patients with chronic kidney disease and hypertension.

Fujisaki K, Tsuruya K, Nakano T, Taniguchi M, Higashi H, Katafuchi R, Kanai H, Nakayama M, Hirakata H, Kitazono T; Impact of Combined Losartan/Hydrochlorothiazide on Proteinuria in Patients with Chronic Kidney Disease and Hypertension (ILOHA) Study Investigators. Fujisaki K, et al. Hypertens Res. 2014 Nov;37(11):993-8. doi: 10.1038/hr.2014.110. Epub 2014 Jun 26. Hypertens Res. 2014. PMID: 24965167 Clinical Trial.

8

Fibroblast growth factor 23, but not parathyroid hormone, is associated with urinary phosphate regulation in patients on peritoneal dialysis.

Yamada S, Tsuruya K, Tokumoto M, Yoshida H, Hasegawa S, Tanaka S, Eriguchi M, Nakano T, Masutani K, Ooboshi H, Kitazono T. Yamada S, et al. Among authors: tanaka s. Ther Apher Dial. 2015 Feb;19(1):73-80. doi: 10.1111/1744-9987.12221. Epub 2014 Sep 4. Ther Apher Dial. 2015. PMID: 25195562

9

Prognostic impact of serum bilirubin level on long-term renal survival in IgA nephropathy.

Tanaka S, Ninomiya T, Masutani K, Nagata M, Tsuchimoto A, Tsuruya K, Kitazono T. Tanaka S, et al. Clin Exp Nephrol. 2015 Dec;19(6):1062-70. doi: 10.1007/s10157-015-1096-0. Epub 2015 Feb 21. Clin Exp Nephrol. 2015. PMID: 25700934

10

Successful treatment of massive proteinuria and severe chyluria by inhibition of cholesterol absorption with ezetimibe in a patient with filariasis.

Tanaka S, Tsuruya K, Tsuchimoto A, Eriguchi M, Kitazono T. Tanaka S, et al. Clin Kidney J. 2012 Oct;5(5):449-52. doi: 10.1093/ckj/sfs110. Clin Kidney J. 2012. PMID: 26019826 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

13,804 results

Search Page

Filters